MicroPort NeuroTech (HKSE:02172) Cash-to-Debt : 16.37 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is MicroPort NeuroTech Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. MicroPort NeuroTech's cash to debt ratio for the quarter that ended in Dec. 2023 was 16.37.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, MicroPort NeuroTech could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for MicroPort NeuroTech's Cash-to-Debt or its related term are showing as below:

HKSE:02172' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.45 Med: 5.41 Max: 16.37
Current: 16.37

During the past 5 years, MicroPort NeuroTech's highest Cash to Debt Ratio was 16.37. The lowest was 0.45. And the median was 5.41.

HKSE:02172's Cash-to-Debt is ranked better than
76.57% of 858 companies
in the Medical Devices & Instruments industry
Industry Median: 1.895 vs HKSE:02172: 16.37

MicroPort NeuroTech Cash-to-Debt Historical Data

The historical data trend for MicroPort NeuroTech's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

MicroPort NeuroTech Cash-to-Debt Chart

MicroPort NeuroTech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

0.45

1.29

5.41

12.83

16.37

MicroPort NeuroTech Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial			5.41	7.12	12.83	15.79	16.37

Competitive Comparison of MicroPort NeuroTech's Cash-to-Debt

For the Medical Devices subindustry, MicroPort NeuroTech's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MicroPort NeuroTech's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MicroPort NeuroTech's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where MicroPort NeuroTech's Cash-to-Debt falls into.

MicroPort NeuroTech Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

MicroPort NeuroTech's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1098.897	/	(26.017	+	41.098)
	=	16.37

MicroPort NeuroTech's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1098.897	/	(26.017	+	41.098)
	=	16.37

MicroPort NeuroTech (HKSE:02172) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

MicroPort NeuroTech Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of MicroPort NeuroTech's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

MicroPort NeuroTech (HKSE:02172) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MicroPort NeuroTech Ltd (HKSE:02172) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1661 Zhangdong Road, Pudong New Area, Shanghai, CHN

Website

https://www.medneurotech.com

MicroPort NeuroTech Ltd is into the neuro-interventional medical device industry, dedicated to providing innovative solutions for physicians and patients. The company boast a comprehensive portfolio of approved therapeutic products covering all of the three main areas of neurovascular disease, namely hemorrhagic stroke, cerebral atherosclerotic stenosis and acute ischemic stroke.

Executives

Hu Yibin
Biolink Biomedical Ltd.	2201 Interest of corporation controlled by you
Blossom Vision Limited	2201 Interest of corporation controlled by you
Lion Fish Limited	2201 Interest of corporation controlled by you
Suntera Corporate Trustees (hong Kong) Limited	2301 Trustee
Thriving Hope Limited	2201 Interest of corporation controlled by you
Biolink Fund Limited Partnership	2201 Interest of corporation controlled by you
Biolink Limited	2101 Beneficial owner
Microport Scientific Corporation
Microport Scientific Investment Ltd
Maxwell Maxcare Science Foundation Limited
We'tron Capital Limited

MicroPort NeuroTech (HKSE:02172) Headlines

No Headlines